We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

FTC Takes Aim at the Issue of Competition for Biologics and Follow-on Biologics

Robert F. Leibenluft

Robert F. Leibenluft,

Washington, D.C.

Leigh Oliver

13 November 2013
The FTC announced that it will host a one-day workshop on December 10, 2013, in Washington, DC, and is requesting public comments by March 1, 2014, on the topic of competition issues relating to biologics and follow-on biologics. The Notice of the workshop and call for comments, which was published in the Federal Register, indicates that the FTC is focused on the following areas:  
FTC Takes Aim at the Issue of Competition for Biologics and Follow-on Biologics

 

  • The impact of state substitution laws and naming conventions on follow-on competition;
  • How naming conventions may affect follow-on competition, including how state laws and regulations may be structured to facilitate competition while protecting patient health and safety; and
  • Experiences of other countries in enabling follow-on biologic competition.

The FTC for a long time has focused on promoting competition between small-molecule brand and generic drugs, including challenging patent litigation settlements between brand and generic companies that allegedly delay generic entry.  In 2009, the FTC held a workshop and solicited comments on competition involving follow-on biologics, which resulted in publication of the Follow-On Biologic Drug Competition report.  Then, in 2010, Congress passed the Biologics Price Competition and Innovation Act to amend the Public Health Service Act, which outlines the FDA approval process for biologic drugs.  The BPCIA creates a pathway for follow-on biologic competition that, although similar in intent to the Hatch-Waxman Act, is substantially different.  

With the persistent growth of biologic medicines, the FTC is again giving attention to competition issues related to this important class of drugs.  The workshop and comments will undoubtedly serve as an important venue for industry participants to be heard on the issues surrounding competition and an expedited pathway for follow-on biologics.

Authors: Leigh Oliver, Robert Leibenluft

Key words: biologics, follow-on biologics, competition, FTC

Robert F. Leibenluft

Robert F. Leibenluft,

Washington, D.C.

Leigh Oliver

Loading data